RiviereASelakMLantinDLeroyFDe VuystL.Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979. doi:10.3389/fmicb.2016.00979
2.
CaderMZKaserA.Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62(11):1653-1664. doi:10.1136/gutjnl-2012-303955
3.
FasanoA.All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9. doi:10.12688/f1000research.20510.1
4.
O’CallaghanAvan SinderenD.Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol. 2016;7:925. doi:10.3389/fmicb.2016.00925
5.
Cantu-JunglesTMRasmussenHEHamakerBR.Potential of prebiotic butyrogenic fibers in Parkinson’s disease. Front Neurol. 2019;10:663. doi:10.3389/fneur.2019.00663
6.
LiuHWangJHeT, et al. Butyrate: a double-edged sword for health?Adv Nutr. 2018;9(1):21-29. doi:10.1093/advances/nmx009
7.
HolscherHD.Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172-184. doi:10.1080/19490976.2017.1290756
8.
UsudaHOkamotoTWadaK.Leaky gut: effect of dietary fiber and fats on microbiome and intestinal barrier. Int J Mol Sci. 2021;22(14):7613. doi:10.3390/ijms22147613
9.
LauWLTranTRheeCMKalantar-ZadehKVaziriND.Diabetes and the gut microbiome. Semin Nephrol. 2021;41(2):104-113. doi:10.1016/j.semnephrol.2021.03.005
10.
WitkowskiMWeeksTLHazenSL.Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553-570. doi:10.1161/CIRCRESAHA.120.316242
11.
NemetISahaPPGuptaN, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell. 2020;180(5):862-877 e22. doi:10.1016/j.cell.2020.02.016
12.
AndreaniGSogariGMartiAFroldiFDagevosHMartiniD.Plant-based meat alternatives: technological, nutritional, environmental, market, and social challenges and opportunities. Nutrients. 2023;15(2):452. doi:10.3390/nu15020452
13.
SatijaABhupathirajuSNRimmEB, et al. Plant-based dietary patterns and incidence of type 2 diabetes in US men and women: results from three prospective cohort studies. PLoS Med. 2016;13(6):e1002039. doi:10.1371/journal.pmed.1002039
14.
PanBLiuXShiJ, et al. A meta-analysis of microbial therapy against metabolic syndrome: evidence from randomized controlled trials. Front Nutr. 2021;8:775216. doi:10.3389/fnut.2021.775216
15.
de GrootPNikolicTPellegriniS, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut. 2021;70(1):92-105. doi:10.1136/gutjnl-2020-322630
16.
KoopenAWitjesJWortelboerK, et al. Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo- controlled cross-over study. Gut. 2022;71(8):1577-1587. doi:10.1136/gutjnl-2020-323297
17.
PerraudeauFMcMurdiePBullardJ, et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020;8(1):e001319. doi:10.1136/bmjdrc-2020-001319
